[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364194-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364194-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","effect-of-ezh2-regulation-of-the-jak2stat3-signaling-pathway-on-proliferation-and-apoptosis-in-non-small-cell-lung-cancer-cells","Effect of EZH2 regulation of the JAK2/STAT3 signaling pathway on proliferation and apoptosis in non‑small cell lung cancer cells","","Enhancer of zeste homolog 2 (EZH2) is frequently overexpressed in non-small cell lung cancer (NSCLC) and correlates with aggressive tumor behavior and poor patient prognosis, yet its detailed molecular mechanisms in NSCLC remain unclear. EZH2 expression was assessed using publicly available databases, and EZH2 function was disrupted via shRNA knockdown in NCI-H1299 and A549 NSCLC cell lines. Proliferation, migration, invasion, apoptosis, and colony formation were evaluated with CCK-8, Transwell, flow cytometry, and colony assays. JAK2/STAT3 involvement was tested by western blotting and rescue using a JAK2 agonist, with in vivo confirmation in a xenograft mouse model.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/effect-of-ezh2-regulation-of-the-jak2stat3-signaling-pathway-on-proliferation-and-apoptosis-in-non-small-cell-lung-cancer-cells/364194/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/effect-of-ezh2-regulation-of-the-jak2stat3-signaling-pathway-on-proliferation-and-apoptosis-in-non-small-cell-lung-cancer-cells/364194.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does EZH2 play in non-small cell lung cancer?","Question",{"text":63,"@type":64},"EZH2 is frequently overexpressed in NSCLC and is associated with aggressive tumor behavior and poor prognosis. The study investigates how EZH2 contributes to NSCLC progression through signaling regulation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study assess EZH2 effects on cancer cell behavior?",{"text":68,"@type":64},"EZH2 was analyzed using publicly available databases, then knocked down with shRNA in NCI-H1299 and A549 cells. Cell proliferation, migration, invasion, apoptosis, and colony formation were measured using CCK-8, Transwell, flow cytometry, and colony assays.",{"name":70,"@type":61,"acceptedAnswer":71},"How was the involvement of the JAK2/STAT3 pathway tested?",{"text":72,"@type":64},"Western blotting was used to examine JAK2 and STAT3 phosphorylation after EZH2 silencing. Rescue experiments with a JAK2 agonist evaluated whether JAK2 activation reverses the anti-tumor effects of EZH2 knockdown, and xenograft results supported the in vivo relevance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364194,1790193983,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ONCOLOGY REPORTS 56: 184, 2026  \nEffect of EZH2 regulation of the JAK2/STAT3 signaling pathway on proliferation and apoptosis in non‑small cell lung cancer cells  \nSHUANG WU 1 and WEI ZHANG2  \n1  \nDepartment of Cardiothoracic Surgery, Yantaishan Hospital, Yantai, Shandong 264100, P.R. China; 2  \nDepartment of Thoracic Surgery, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China  \nReceived December 24, 2025; Accepted August 10, 2026  \nDOI: 10. 3892/or.2026.9190  \nAbstract. Enhancer of zeste homolog 2 (EZH2) is frequently overexpressed in non‑small cell lung cancer (NSCLC) and is associated with aggressive tumor behavior and poor patient prognosis. However, the molecular mechanisms through which EZH2 drives NSCLC progression, particularly its interplay with major oncogenic signaling cascades, remain incom‑ pletely defined. EZH2 expression was analyzed using publicly available databases. Functional perturbations were achieved via short hairpin RNA (shRNA)‑mediated knockdown in NCI‑H1299 and A549 NSCLC cell lines. Cell proliferation, migration, invasion, apoptosis, and colony formation were assessed using Cell Counting Kit‑8, Transwell, flow cytometry and colony formation assays, respectively. Involvement of the JAK2/STAT3 pathway was examined by western blotting and rescue experiments using a JAK2 agonist. In vivo validation was conducted using a xenograft mouse model. EZH2 was markedly upregulated in NSCLC tissues. Its silencing markedly suppressed cell proliferation, impaired migratory and invasive capacities, induced apoptosis, and curtailed tumor growth in vivo. Mechanistically, EZH2 silencing attenuated the phos‑ phorylation of both JAK2 and STAT3. Crucially, the anti‑tumor effects of EZH2 knockdown were effectively reversed by JAK2 agonism, positioning EZH2 upstream of the JAK2/STAT3 axis. The present study demonstrated that EZH2 promotes NSCLC progression through activation of the JAK2/STAT3 signaling pathway, identifying the EZH2‑JAK2/STAT3 axis asa potential therapeutic vulnerability in this malignancy.  \nIntroduction  \nLung cancer remains the leading cause of cancer‑related mortality worldwide. In 2022, ~2.5 million new cases were  \nCorrespondence to: Professor Wei Zhang, Department of Thoracic Surgery, Yantai Yuhuangding Hospital, 20 Yuhuangding East Road 264000, Yantai, Shandong 264000 P.R. China  \nE‑mail: [ytyhdyyxwkzw@sina.com](ytyhdyyxwkzw@sina.com)  \nKey words: non‑small cell lung cancer, enhancer of zeste homolog 2, JAK2/STAT3, proliferation, apoptosis  \ndiagnosed, accounting for 12.4% of all cancer diagnoses, with an estimated 1.8 million deaths representing 18.7% of global cancer mortality (1) . Non‑small cell lung cancer (NSCLC) constitutes ~85% of all lung cancer cases . Over the past decade, treatment paradigms for NSCLC have tran‑ sitioned from conventional cytotoxic chemotherapy toward biomarker‑driven precision medicine, substantially improving patient outcomes and quality of life (2,3) . Following the landmark discovery linking epidermal growth factor receptor (EGFR) mutations to gefitinib efficacy, inhibitors targeting actionable drivers, including EGFR, anaplastic lymphoma kinase, ROS proto‑oncogene 1, B‑Raf proto‑oncogene, rear‑ ranged during transfection, neurotrophic tyrosine receptor kinase, mesenchymal‑epithelial transition factor and kirsten rat sarcoma viral oncogene, have been integrated into clinical practice, conferring marked survival advantages (3‑5) .  \nNevertheless, precision therapy in NSCLC confronts persistent challenges . First, only ~25% of patients harbor currently targetable driver mutations (6); Second, median progression‑free survival on targeted agents frequently remains below 20 months, constrained by acquired resistance mechanisms such as secondary mutations, bypass pathway activation, and histologic transformation (7); Third, immune checkpoint inhibitors targeting programmed cell death protein‑1/programmed death‑ligand 1(PD‑L1) demonstrate efficacy predominantly ","cbCainZJvJnnpAN2","https://ap.wps.com/l/cbCainZJvJnnpAN2","pdf",8780327,11,"English","# Introduction\n## Epidemiology and current NSCLC treatment challenges\n## Role of JAK2/STAT3 in tumor progression\n## EZH2 as an epigenetic regulator and prior evidence of EZH2–JAK2/STAT3 crosstalk\n## Rationale for investigating EZH2–JAK2/STAT3 interaction in NSCLC","[{\"question\":\"What role does EZH2 play in non-small cell lung cancer?\",\"answer\":\"EZH2 is frequently overexpressed in NSCLC and is associated with aggressive tumor behavior and poor prognosis. The study investigates how EZH2 contributes to NSCLC progression through signaling regulation.\"},{\"question\":\"How did the study assess EZH2 effects on cancer cell behavior?\",\"answer\":\"EZH2 was analyzed using publicly available databases, then knocked down with shRNA in NCI-H1299 and A549 cells. Cell proliferation, migration, invasion, apoptosis, and colony formation were measured using CCK-8, Transwell, flow cytometry, and colony assays.\"},{\"question\":\"How was the involvement of the JAK2/STAT3 pathway tested?\",\"answer\":\"Western blotting was used to examine JAK2 and STAT3 phosphorylation after EZH2 silencing. Rescue experiments with a JAK2 agonist evaluated whether JAK2 activation reverses the anti-tumor effects of EZH2 knockdown, and xenograft results supported the in vivo relevance.\"}]","Effect of EZH2 regulation of the JAK2/STAT3 signaling pathway on proliferation and apoptosis in non‑small cell lung cancer cells | PDF",1790156313,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/220e4606db53953c70c404bb7db7b8d7.webp",983,1357,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/589e10e3148827aee12284a01381aa55.webp",982,1356,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c256e828841f2b47584c7a6628910532.webp",981,1354,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22395cd57cd7bb40bd0e39220a820ec1.webp",980,1353]